弥漫大B细胞淋巴瘤(DLBCL)是最常见的一类非霍奇金淋巴瘤(NHL),占NHL30%-40%[1],也是一组异质性疾病,其临床特征、组织学、免疫表型、细胞遗传学和分子遗传学在不同的病例之间会有所差异。尽管联合化疗能使40%-50%的患者达到持续缓解,但仍有许多DLBCL患者不能缓解或缓解后复发 Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for 30% to 40% of NHL [1] and is also a heterogeneous group of patients with clinical features, histology, Immunophenotyping, cytogenetics and molecular genetics can vary from case to case. Although combination chemotherapy can achieve sustained remission in 40% to 50% of patients, many patients with DLBCL can not relieve or relieve recurrence